Company Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types.
Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria.
Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria.
The company was incorporated in 2010 and is based in San Carlos, California.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jun 20, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 90 |
| CEO | John A. Orwin M.B.A. |
Contact Details
Address: 835 Industrial Road, Suite 400 San Carlos, California 94070 United States | |
| Phone | 650-595-2595 |
| Website | atreca.com |
Stock Details
| Ticker Symbol | BCEL |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001532346 |
| CUSIP Number | 04965G109 |
| ISIN Number | US04965G1094 |
| Employer ID | 27-3723255 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John A. Orwin M.B.A. | President, Chief Executive Officer, Director and Principal Financial Officer |
| Dr. Tito A. Serafini Ph.D. | Founder and Director |
| Rick Ruiz | Principal Accounting Officer |
| Courtney J. Phillips J.D. | General Counsel and Corporate Secretary |
| Roger Richard Ruiz | Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | DEFM14A | Filing |
| Apr 11, 2024 | PREM14A | Filing |
| Apr 1, 2024 | 15-12G | Securities registration termination |
| Apr 1, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 1, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 1, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 1, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 1, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |